N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive with the update released this week.
Share talk spoke with Nigel Theobald, covering the latest announcement and asking him about the market response to news being released by the company, current share price and how often do they have to update the markets?
Have you fully funded all current work streams in Q1/2 in 2022, yes we have more than sufficient funds to carry out the work planned, just a few of the topics raised in the podcast.
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
Listen On
Also Listen
-
Zak Mir talks to Charles Dickson, CEO of Roadside Real Estate
We spoke with Charles Dixon, CEO of Roadside Real Estate, to unpack the company' -
Zak Mir Speaks with Fiinu CEO Dr. Marko Sjoblom on New Strategic Partnership
Zak Mir caught up with Dr. Marko Sjoblom, Chief Executive Officer of Fiinu Plc, -
Tim McCarthy, Chief Executive Officer of ImmuPharma PLC talks to Zak Mir
Zak Mir talks to Tim McCarthy, CEO of Immupharma, the speciality biopharmaceutic -
Zak Mir talks to Ippolito Cattaneo, Chief Executive Officer of Ajax Resources Plc
Zak Mir talks to Ippolito Cattaneo, CEO of Ajax Resources, in the wake of this w